News

Pristima suite is the fully integrated preclinical and vivarium management solution that connects to enterprise quality & compliance management processes. Xybion Preclinical Solutions vice president Carlos Frade said

As per the agreement, AstraZeneca will take over Ardea for $32 per share, also adding RDEA3170, a next-generation selective URAT1 inhibitor currently in Phase I development, to its

The US label changes are the result of discussions with the FDA, following cases of heart attacks and strokes in patients who took Gilenya. The drug is contraindicated

The investment is also aimed to set up a multiproduct facility in Visakhapatnam, India, and to upgrade existing facilities, reports Business Standard. The multiproduct manufacturing facility is expected

The acquisition, which is expected to close within 30 days, will merge XenneX into LifeMap Sciences. The deal is expected to integrate GeneCards and PanDaTox in a centralized

The companies have also been requesting the government to upgrade the basic technical teaching systems, for better trained human source to manage the sector on long term sustainable

The oral oxazolidinone antibiotic targets infections due to multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). MicuRx president and chief executive officer Zhengyu

Flutiform is a fixed-dose combination long-acting beta-agonist, formoterol fumarate and the prescribed corticosteroid, fluticasone propionate, designed for treating asthma patients. Flutiform uses SkyePharma’s patented SkyeDry formulation technology which

The OTC products being divested include Phillips MOM, Solpadeine, Dequadin, Cartia and Zantac. The deal follows agreements reached in December 2011 and last month to divest the brands